| |
Control |
P Group |
PD group |
PR group |
PRD group |
R group |
RD group |
VitD group |
| RBCs (X106/μl) |
9.3 ± 2.1 |
8.7 ± 1.1 |
9 ± 0.9 |
7.9 ± 0.6a,c |
9.15 ± 0.8b,d |
7.25 ± 0.45a,b,c,e |
9.3 ± 0.9d,f |
8.9 ± 0.5d,f |
| Hb (g/dL) |
15.5 ± 1.07 |
14.9 ± 0.7 |
15.2 ± 0.8 |
13.1 ± 0.5a,b,c |
15.54 ± 0.5d |
12.6 ± 1a,b,c,e |
14.9 ± 0.6d,f |
15.1 ± 0.8d,f |
| PCV (%) |
46.4 ± 7.1 |
42.3 ± 3.1 |
43.1 ± 1.4 |
41.9 ± 1.3 |
45.1 ± 0.6 |
42.1 ± 2.7 |
42.9 ± 1.3 |
44.9 ± 1.8 |
| MCV (fL) |
61 ± 3.5 |
62.7 ± 3.3 |
62.1 ± 0.8 |
61.1 ± 2.9 |
59.2 ± 3.6 |
64.3 ± 4.2 |
59.5 ± 1.6 |
61.3 ± 1.8 |
| MCH (pg) |
17.6 ± 0.9 |
17.8 ± 0.9 |
17.7 ± 0.4 |
17.5 ± 0.7 |
17.1 ± 0.6 |
17.6 ± 0.7 |
17.4 ± 0.5 |
17.4 ± 0.7 |
| MCHC (pg/dL) |
34.7 ± 1 |
33.8 ± 0.5 |
35.9 ± 0.6a,b |
34.5 ± 1c |
36.8 ± 1a,b,d |
34.4 ± 0.9c,e |
35.8 ± 0.6a,b,d,f |
34 ± 0.8c,e,g |
| Serum EPO (ng/mL) |
2.3 ± 0.8 |
1.92 ± 0.3 |
2.9 ± 0.8a,b |
0.63 ± 0.15a,b,c |
1.9 ± 0.6c,d |
0.7 ± 0.4a,b,c,e |
2.1 ± 0.9c,d,f |
2.9 ± 0.4a,b,d,e,f,g |
| Kidney EPO (ng/mL) |
4.9 ± 0.7 |
4.2 ± 0.4 |
6.1 ± 1.1a,b |
2 ± 0.6a,b,c |
4.4 ± 0.8c,d |
2.3 ± 0.7a,b,c,e |
4 ± 1.1c,d,f |
5.8 ± 1a,b,d,e,f,g |
|
